Memolek

Memantine, the active ingredient in Memolek, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, where it helps to improve cognition and daily functioning.

GNH USA supplies Memolek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required and comprehensive regulatory support.

Memolek (memantine) acts on the glutamatergic system and is used in the management of Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): improves cognitive function and daily living activities. - Behavioral symptoms in Alzheimer’s disease: may reduce agitation and aggression. - Functional decline in Alzheimer’s disease: helps maintain independence in routine tasks.

Memolek may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reaction (anaphylaxis) - Hepatic dysfunction

When prescribing Memolek, clinicians should consider specific patient factors and follow safety recommendations. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: use with caution and assess liver enzymes regularly. - History of seizures: monitor for increased seizure activity. - Elderly patients: start at low dose and watch for confusion or falls. - Concomitant CNS depressants: avoid excessive sedation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Memolek can interact with other medicines, and some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Other NMDA antagonists (e.g., amantadine): may increase neurotoxicity. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): can reduce memantine plasma levels. - High-dose aspirin or NSAIDs: may elevate risk of gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate confusion or cognitive decline. - Diuretics: may affect blood pressure and electrolyte balance.